ArticleTropical medicine and infectious disease2025
Contribution of Respiratory Syncytial Virus to Burden of Lower Respiratory Tract Infections: A Global Analysis of 204 Countries and Territories, 1990-2021.
Article in Tropical medicine and infectious disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immunogenicity of a Recombinant MVA Vector Vaccine Expressing the Prefusion RSV F Protein in Balb/c Mice.Vaccines · 2026Article
- Burden of lower respiratory infections in five East Asian countries from 1990 to 2021: observation, comparison, and forecast from the global burden of disease study 2021.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Respiratory syncytial virus (RSV) is a major cause of morbidity and mortality from lower respiratory infections (LRIs) worldwide. This study analyzes trends in age-standardized death rates (ASDRs) and disability-adjusted life years (DALYs) due to RSV-induced LRIs from 1990 to 2019, using data from the Global Burden of Disease Study 2021 (GBD 2021). The findings show a gradual decline in deaths, ASDR, and DALYs throughout this period. However, these indicators were higher in men than in women, as well as more pronounced in sub-Saharan West Africa. Developed countries exhibited higher ASDR and DALY values than developing countries, with the highest burden observed among children and the elderly in low Socio-demographic Index (SDI) regions. Globally, RSV-induced LRIs have shown a significant reduction in burden, but interventions are still urgently needed-particularly in low SDI areas-to reduce the impact on vulnerable populations. Public health policies focusing on these high-risk groups are essential for addressing the remaining disparities in RSV-related morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.